Charles River Laboratories (CRL) Tops Q3 EPS by 8c; Narrows Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations
November 9, 2017 7:00 AM ESTThird-Quarter Revenue of $464.2 Million
Third-Quarter GAAP EPS of $1.09 and Non-GAAP EPS of $1.30
Updates 2017 Guidance
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2017. Revenue from continuing operations was $464.2 million, an increase of 9.0% from $425.7 million in the third quarter of 2016. Revenue growth was driven primarily by the Discovery and Safety Assessment and Manufacturing Support segments.
The acquisitions of Agilux Laboratories and Brains On-Line contributed 2.7% to consolidated third-quarter revenue growth, both on a reported... More
